Related by context. All words. (Click for frequent words.) 67 Randomized Evaluation 66 PHASE III 65 IN PATIENTS WITH 65 STENT 65 PRECISE 65 PROTEGE 64 Prospective Randomized 64 MAGELLAN 64 DIAGNOSTIC 63 TISSUE 63 INITIATE 63 Bosutinib 62 CABANA 62 COMPANION 62 COMPONENT 62 VITALITY 62 POWER TOOLS 62 Severe Sepsis 62 THERAPEUTIC 62 Parathyroid Hormone 61 MIST II 61 RECOVER 61 STUDY RESULTS 61 STEM CELL 61 Pivotal Trial 61 phase IIIb 61 STEERING 61 UNLOAD 61 AND SERVE 61 IMPACTS 61 FUEL CELLS 61 Resynchronization 61 Interferon beta 1a 60 AMEREN 60 DEFER 60 ASSURE 60 PEDIATRIC 60 Cypher Sirolimus 60 PREVAIL 60 PRELUDE 60 Dose Ranging Study 60 MORTALITY 60 PREVENTION OF 60 Drug Eluting Stent System 60 COURSE FOR 60 Initiate Phase 60 NATURE OF 60 MEDICAL PRODUCTS 60 PROWESS 60 renal artery stenting 60 FACTS ABOUT 60 ASSERT 60 Carotid 59 TECHNOLOGIES CORPORATION 59 SENSORS 59 Adjunctive 59 THE VALUE OF 59 CURRICULUM 59 PROCEDURE FOR 59 ESTABLISH 59 Acute Myocardial Infarction 59 FOR EDUCATION 59 Schizophrenia Treatment 59 Initiated Phase 59 MEASUREMENT 59 DUROS 59 EXTENDS ITS 59 ILLUSTRATE 59 TRAINING FOR 59 Recurrent Glioblastoma 59 BrachySil ™ 59 FOR HEALTH 59 AUTOMATED 59 HEART HEALTHY 59 PHASE II 59 II Clinical Trial 59 THYROID 58 SORT OUT 58 Sirolimus eluting 58 REVIVE 58 EXAMINE 58 BIOMEDICAL 58 PROCEED 58 Percutaneous Tibial Nerve Stimulation 58 MOBILITY 58 STRENGTHENING THE 58 IMPLANT 58 AVENTIS 58 Unstable Angina 58 REALISM 58 Long Term Efficacy 58 COMPRESSION 58 Multicenter 58 COPERNICUS 58 GENETICALLY MODIFIED 58 ASTEROID 58 Endoprosthesis 58 DATA CENTER 58 THERAPIES 58 Intravitreal 58 EXTENDING THE 58 Mycophenolate Mofetil 58 IN ONTARIO 58 NO EASY 58 STRATEGIC ALLIANCE 58 SLICES 58 MOVE IN 58 PROCEDURE 58 EFFECTS ON 58 TECHNOLOGIST 58 Phase IIIb 58 STATUTORY 58 CARDIAC 58 CARDIO 58 INTRODUCES THE 58 PROCESS FOR 58 RE MODEL 58 SENSOR 58 PAYS FOR 57 OFFERS NEW 57 PROFILES OF 57 NATURE AND 57 Intravascular 57 TENDER OFFER FOR 57 ANTI AGING 57 SHRINKS 57 ANNOUNCES ANNUAL 57 CONNECTION BETWEEN 57 Ranolazine 57 ENERGY LIMITED 57 INTEGRATED 57 Acute Ischemic Stroke 57 dual endothelin receptor antagonist 57 WEIGH 57 HONORED FOR 57 NCT# ClinicalTrials.gov 57 CANCELLATION OF 57 See CLINICAL PHARMACOLOGY 57 Prospective Randomized Trial 57 ENROLLMENT 57 Levacor TM 57 METEOR 57 DRUG DEVELOPMENT 57 OFFSET 57 Small Vessel 57 COST EFFECTIVE 57 Randomised 57 EURIDIS 57 TOPICAL 57 STARFlex R 57 topically administered 57 PRECISION 57 GENERATOR 57 Biolimus A9 57 CASH ADVANCE 57 ASSESSMENT OF 57 beta 1a 57 FUNCTIONAL 57 MICROSCOPE 57 CONQUER 57 TRANSPORTED TO 57 PFO migraine 57 BEATER 57 MINDSET 57 CELLO 56 TROPIC 56 Embolic Protection Device 56 Ziprasidone 56 Dual Antiplatelet Therapy 56 INSPECT 56 Embolic Protection System 56 Liposomal 56 MEMBERSHIP IN 56 INFORMATION SYSTEMS 56 YOUR BRAIN 56 Percutaneous Transluminal Coronary Angioplasty 56 FOR SUCCESS 56 CLINICAL PHARMACOLOGY 56 PATENT 56 Novacor II 56 catheter occlusion 56 CONT 56 SIMULATED 56 Ablation System 56 DO WELL 56 DATA PROCESSING 56 transcranial Doppler ultrasound 56 ASSESS 56 Novacor R 56 TRANSPLANTS 56 VERIFICATION 56 THE BRAIN 56 Acute Decompensated Heart Failure 56 gefitinib Iressa 56 Phase IIIb clinical 56 SECURITY SYSTEM 56 TM Drug Eluting 56 SHIFTS 56 CONSCIOUS 56 CLEAN WATER 56 TRUST AND 56 O MATIC 56 EVALUATE 56 SEPTIC 56 ALARMS 56 CANCERS 56 TRANSFER TO 56 DRIVEN TO 56 ENABLE 56 Carotid Artery Stenting 56 MEND CABG 56 Granted Orphan Drug 56 FOR CASH 56 GRADUATES FROM 56 AVASTIN 56 GET PAST 56 HORIZONS 56 EVRA 56 BODY AND 56 OF EXCELLENCE 56 NAVIGATOR 56 humanized monoclonal 56 fosbretabulin 56 Aneurysm Repair 56 ACCLAIM 56 NATIONAL HEALTH 56 TOOLS AND 56 OUTCOMES 56 MEND CABG II 56 metastatic malignant 56 Endovascular System 56 multicenter randomized controlled 56 FOR TEACHERS 56 TM Everolimus Eluting 56 PROMUS TM 56 OF THE FUTURE 56 BORSA 56 RECEIPTS 55 INCOME TRUST 55 TOYOTA COROLLA 55 SUMS 55 Phase 2b kidney transplant 55 Drug Eluting Stents 55 TECHNOLOGY INC. 55 Neoadjuvant 55 ID NCT# 55 ADJUSTING TO 55 multicenter prospective 55 PILOT PROGRAM 55 Recombinant Human 55 DEDUCTION 55 SETTLEMENT OF 55 RETHINKING 55 REGISTERING 55 Vascugel ® 55 Occluded 55 STRUCTURED 55 Quinamed 55 REVEAL 55 DESTROY THE 55 ATTRACT 55 DRAINAGE 55 RE COVER 55 GENES 55 Chemoradiation 55 ASTHMA 55 SHARES RISE 55 PROTECT YOUR 55 TAXOTERE R 55 RIGHTS ISSUE 55 Arimidex Tamoxifen Alone 55 WALK TO 55 WEAKENING 55 CRISTAL 55 SENTINEL 55 ENDEAVOR III 55 MICROPHONE 55 AND TRAINING 55 fallopian tube cancers 55 Phase Ib II 55 MORE GOALS 55 COMPLIANCE 55 IIIb 55 EMBLEM 55 LOST HIS 55 COMPARISON TO 55 ACCELERATION 55 CLOSE TO THE 55 GRANT FOR 55 Phase IIb III 55 MADE EASY 55 RE LY ® 55 ENERGY CONSERVATION 55 SEEDS OF 55 INSIGHT INTO 55 CARRA 55 MANAGEMENT TEAM 55 multicentre randomized 55 Emboshield 55 CONTRAINDICATIONS 55 'S CUP 54 REHABILITATION 54 LATERAL 54 COMPLETION 54 daily subcutaneous injections 54 PROCESSING 54 multicenter randomized placebo controlled 54 UNDERWRITERS 54 EASEMENT 54 ASSAY RESULTS 54 GASTRIC 54 HOSP 54 Phase #b/#a clinical 54 WINDOW OF 54 PATH TO 54 BUILDING UP 54 CABERNET 54 MODERNIZATION 54 Platinol ® 54 BASIS OF 54 STRIDE PD 54 TRIUMPH 54 Prochieve R 8 54 INFORMATICS 54 DESIGN BUILD 54 THE QUEST FOR 54 prospective multicenter randomized 54 APPLIES 54 INCREASES IN 54 inhaled AAT 54 HeartMate R 54 pharmacodynamic PD 54 FINESSE 54 CONNECTOR 54 PERFORMED 54 GISSI 54 STAGE SET FOR 54 DYNAMICS 54 USES 54 MY MOUTH 54 STOVE 54 GAME IS 54 BIPOLAR 54 AND PRAY 54 eluting stent 54 LOCAL FOOD 54 FIRE SAFETY 54 INTERFACE 54 END USER 54 CHARLES SCHWAB 54 PROMUS R 54 COMMUNITY ARTS 54 TO SPEAK AT 54 Hsp# Inhibitor 54 CHASERS 54 certolizumab 54 Restenosis 54 HuMax 54 POETIC 54 CONTINUING EDUCATION 54 TRADING ON 54 PUBLIC HEALTH 54 INNOVATION AND 54 AND EXCHANGE 54 transurethral 54 LOOKING FOR NEW 54 Accelerated Partial Breast Irradiation 54 FIRST ANNUAL 54 ENVISION 54 ENGINEERING AND 54 WORK WEEK 54 QUEST FOR 54 Thrombolysis 54 TAXUS ATLAS 54 Current Controlled Trials 54 TMC# C# 54 FOR CHANGE 54 PRoFESS 54 NAVIGATION 54 Betaferon R 54 SURGICAL 54 ALTITUDE 54 COOKING FOR 54 APTIVUS 54 Fabry Disease 54 EARNS TOP 54 HOW WE 54 Coronary Artery Bypass Graft 54 REPLACE 54 FOODS INC. 54 TUMT 54 multikinase inhibitor 54 ELIMINATE THE 54 Cloretazine 54 Implantable Cardioverter Defibrillator ICD 54 Stenting Trial 54 Myelodysplastic Syndrome MDS 54 REGISTRY 54 FOR HIMSELF 54 SOLUTIONS INC. 54 TQT 53 Atrial Flutter 53 ENTRANCE 53 CD HORIZON 53 Aurora Kinase 53 Randomized controlled 53 prospective multicenter 53 WHAT DO YOU DO 53 ENDEAVOR 53 SEPARATION 53 INSTRUMENT 53 WAY OUT OF 53 LONG LIFE 53 PHYSICIAN 53 Microwave Ablation System 53 NAVISTAR R 53 Myeloid 53 OF OPTIONS 53 Thrombolytic 53 MARKETING DIRECTOR 53 INTERPRETED 53 RESEARCH GROUP 53 Immunotherapeutic 53 CONSULTATION ON 53 SEARCH FOR THE 53 LIKES TO 53 Pemetrexed 53 CHAMPION PCI 53 ANNUAL REPORT 53 PUBLIC INPUT 53 Lymphoma Patients 53 assessing T DM1 53 Levacor 53 BUS SERVICE 53 Carotid Revascularization Endarterectomy vs. 53 pioglitazone HCl 53 CORPORATION LIMITED 53 ROOM TO 53 FISHING FOR 53 HORIZONTAL 53 Sibutramine Cardiovascular Outcomes 53 CLEAN ENERGY 53 randomized controlled Phase 53 HAND TO 53 Everolimus Eluting Coronary Stent 53 PHYSICIANS 53 mechanical thrombectomy 53 STRUCTURE 53 Left Atrial Appendage 53 THEY 'VE GOT 53 ADONIS 53 WILL THEY 53 sitaxsentan 53 MAKING THEIR 53 treatment naive genotype 53 PROCRIT R 53 Phase IIA 53 SNAPS 53 TRANSPLANT 53 CLO RP 53 ONTARGET 53 Cysteamine 53 ARDIS 53 BioSTAR ® 53 APPETITE FOR 53 RECOMMENDATIONS 53 Eluting Stent 53 CONNECTS 53 NO NEED FOR 53 LABORATORY 53 GORE TAG ® 53 EVOLUTION 53 HEALTHY LIFE 53 VENDING 53 CALGB # [002] 53 PORTION 53 subcutaneous immunoglobulin 53 Eluting Coronary Stent System 53 GORE TAG Device 53 CASH FOR 53 CHECKER 53 ibandronate 53 selective antagonist 53 PETROLEUM LIMITED 53 AIDED BY 53 RECEIPT 53 REQUEST FOR PROPOSALS 53 IMPLEMENTATION 53 Teflaro treated 53 TASKS 53 TAPAS 53 Cardiac Resynchronization Therapy 53 Kamada AAT 53 liposomal formulation 53 TELIGEN 53 EXTENT OF 53 PERSEUS 53 Fracture Intervention Trial 53 Pegylated Liposomal Doxorubicin 53 POISE 53 HEALTH SYSTEM 53 PARTNERS IN 53 PIPELINES 53 WOMEN TAKE 53 USING THEIR 53 BENEFICIARIES 53 COMPARING THE 53 LVAS 53 Endeavor Drug Eluting 53 PROPERTY TRUST 53 READINESS 53 TEAM LEADER 53 LANDFILL 53 ALLEGRO 53 FERGUSON 'S 53 relapsing multiple sclerosis 53 PROCESSOR 53 DOWNWARD 53 FINANCIAL MANAGEMENT 53 Melphalan 52 MINERALS INC. 52 nimodipine 52 selective A2A adenosine receptor 52 MEDIFAST 52 REVEAL Registry 52 Dalbavancin 52 RELIANT Trial 52 REVLIMID lenalidomide 52 PIONEER 52 PRECEDENT 52 Advanced Heart Failure 52 prospective randomized controlled 52 YOUR TEETH 52 GREEN BUILDING 52 NEVO 52 Anticoagulation 52 IN.PACT 52 multicenter Phase II 52 THE POST OFFICE 52 YOUR CONFIDENCE 52 EXCITE 52 WEIGHTS 52 OPTION 52 Alfimeprase 52 SIX WEEK 52 SLOW TO 52 UPGRADE TO 52 TUMBLING 52 Cytochrome P# 52 gemtuzumab ozogamicin 52 icatibant 52 APEX PD 52 APPLICATION 52 STEPS TO 52 HAVE SOME 52 substudy 52 SOARS 52 EVALUATIONS 52 STARFlex ® 52 PREVENT IV 52 ASSURANCE 52 TAXUS Element Paclitaxel Eluting 52 ANOTHER MAJOR 52 DIPLOMA 52 ZYBRESTAT TM 52 reslizumab 52 multicentre randomized controlled 52 Bivalirudin 52 REAL ESTATE MARKET 52 OF CHANGE 52 Thrombin 52 BRILINTA 52 Phase III randomized controlled 52 NO ORDINARY 52 LOVES TO 52 Lamotrigine 52 endothelin antagonists 52 GW# [003] 52 multicentre randomized double 52 PROMUS Element 52 FOR YOUTH 52 GORE ® 52 ENDEAVOR IV 52 Febuxostat 52 RIVA D. 52 ROBOTICS 52 REGENTS 52 KN# [001] 52 glycoprotein GP IIb IIIa 52 Refractory Angina 52 INVENTION 52 docetaxel cisplatin 52 controlled multicenter Phase 52 FOUNDATION FOR 52 EXCOR R 52 PROJECT MANAGEMENT 52 DUTY OF 52 Phase Ib clinical 52 DIVERSION 52 MAJOR INTERESTS IN SHARES 52 Cinacalcet HCl 52 VALVE 52 somatostatin analog 52 CONSERVE 52 pegylated recombinant 52 OPTIMUM 52 Feasibility Trial 52 MATHEMATICS 52 SEPET TM 52 FRONT RUNNING 52 ACCELERATE 52 HeartMate ® 52 FOR THOUGHT 52 INDIA FUND 52 HEART AND 52 TAXUS Express2 52 BLP# Liposome Vaccine 52 Alagebrium 52 CITI INSTALMENTS 52 CAMPAIGN FOR 52 Zemplar Capsules 52 AVANDIA 52 FOR FURTHER INFORMATION ABOUT 52 MAXIMA 52 uremic pruritus 52 Teysuno 52 CAPTURE 52 Aortic Valve 52 XYOTAX TM 52 SHAKES UP 52 BrachySil TM 52 Stent Graft 52 LIKE YOUR 52 UPLYSO 52 DENS 52 REGARDS 52 IS EVERYTHING 52 lapatinib Tykerb 52 Phase III Psoriasis 52 vidofludimus 52 SUPERVISORY 52 VENT 52 TRUST COMPANY 52 STRIDES 52 lanreotide 52 pharmacokinetic PK 52 Drug Eluting Stent 52 WallFlex Biliary RX 52 carotid artery stenting CAS 52 MEDAL 52 Tacrolimus 52 ARCHITECTURAL 52 prucalopride 52 INTERNATIONAL LIMITED 52 CLEARED TO 52 MESI 52 EchoCRT 52 selective A1 adenosine 52 COMMITTEE OF 52 SMALL BIZ 52 Vascular Stent 52 SPRINT 52 SCHOOL SUPPLIES 51 CentriMag 51 SWELL 51 MKC# MKC# PP 51 DEADLINE TO 51 TASKi3 51 OF ELECTRONIC 51 REALITY Trial 51 DREAM ALIVE 51 Catheter Ablation 51 Aflibercept 51 Anti Platelet 51 ARTERY 51 Ranibizumab 51 pharmacokinetic PK study 51 COURT MARTIAL 51 prospective multicentre 51 KOMEN 51 COMPLY 51 difluprednate 51 EFFICIENT 51 PROJECTOR 51 randomized multicenter 51 CURVES 51 Dual Opioid 51 SOILS 51 Endurant 51 STRAIGHT FROM THE 51 EXAMINATION 51 inhaled treprostinil 51 ENGINEERING SERVICES 51 LIVE WELL 51 LATITUDE 51 NEW PLANT 51 BREAST CANCER AWARENESS 51 FREE COMPUTER 51 melphalan prednisone 51 EXPERIMENTS 51 EXPERIENCE IN 51 ENVIRONMENTAL PROTECTION AGENCY 51 AOD# [002] 51 THE PRIMARY 51 coflex 51 BAIE 51 AND EDUCATION 51 aripiprazole Abilify 51 trodusquemine 51 CUMULATIVE 51 Sanvar R 51 FAMILY HEALTH 51 PREFERRED 51 STAND FOR 51 EOquin TM 51 GORE VIABAHN Endoprosthesis 51 PAY PER 51 INNOVATION IN 51 SECRET TO 51 Spine Patient Outcomes 51 Xanafide 51 Temsirolimus 51 Glufosfamide 51 ACCESSING 51 FINDER 51 phase IIb clinical 51 docetaxel Taxotere ® 51 VESTASYNC II trial 51 DECISION MAKERS 51 Keryx Biopharma 51 LOADING 51 HALTER 51 LAUNCHES WEBSITE 51 HepDirect prodrug 51 RHEO 51 GORE TAG 51 CORD II 51 Platinol ® cisplatin 51 DUNHILL 51 TEXTBOOK 51 GETTING YOUR 51 TO REPEAT 51 PROTECT AF 51 JUST BE 51 ARE ON 51 OF FREEDOM 51 Liberte TM 51 OUT OF HIS 51 GIFT OF 51 SUBSCRIBING 51 GLOBAL FUND 51 orally administered inhibitor 51 XIENCE PRIME TM 51 CLEAN AND 51 NN# [001] 51 CONSOLIDATION OF 51 Phase IIa trials 51 Exemestane 51 PENSION PLANS 51 ritonavir boosted 51 ADVANCE PD 51 AFFINITY 51 CHIROPRACTIC 51 DEPOSIT 51 WITH DISABILITIES 51 STARFlex 51 PREOS R 51 MASONRY 51 COURT DECISION 51 FIGHTING FOR 51 formoterol fumarate 51 AND BURN 51 RE LY 51 Self Expanding Stent 51 vein ablation 51 BioSTAR TM 51 Pivotal Phase II 51 RESOURCES LTD 51 ENERGY EFFICIENCY 51 HOLDING THE 51 LATE FEES 51 WILSHIRE 51 PARTICIPATION 51 FOR HUMANITY 51 everolimus eluting stents 51 VOLTAGE 51 AND TRADE 51 CAPELLA 51 APOLLO 51 System AERS 51 WATCHMAN 51 SERVING UP 51 INTERVAL 51 OF CHOICE 51 BRIGHTEST 51 Resten MP 51 LEARNS 51 TOPPERS 51 LIFESAVING 51 GLOBAL HEALTH 51 FASLODEX 51 Nitinol Stent 51 FISH AND 51 SIGNAL 51 WATCH YOUR 51 CHAPTERS 51 BAG OF 51 ECOSYSTEM 51 AVAIL 51 PLACES TO 51 CardioFit 51 Anavex #-# 51 prospective randomized multicenter 51 CONCEPTS 51 REFLEX 51 direct thrombin inhibitors 51 placebo controlled Phase III 51 antibody MAb 51 AIM HIGH 51 Catena ® 51 MEDAL OF 51 IV Busulfex 51 V Everolimus Eluting Coronary 51 randomized Phase IIb 51 ATTACH 51 Lucanix 51 LISTED ON 51 immunomodulatory therapy 51 SLEEVE 51 Subcutaneous 51 LITES 51 SHARE ISSUE 51 THEY TELL 51 BCIRG 51 GIRLS TEAM 51 WITHOUT FEAR 51 AS SOON AS POSSIBLE 51 CryoPlasty 51 HEALTHCARE PROVIDER 51 AND FAMILY 51 TRELSTAR R 51 antiarrhythmic drug 50 Lipid Lowering 50 FULFILLING 50 LEADERSHIP AWARD 50 WORK EXPERIENCE 50 ENERGY EFFICIENT 50 SUTENT ® 50 SHARING THE 50 METIS 50 EXERCISE OF 50 Percutaneous Coronary Interventions 50 Cypher Stent 50 ON TUESDAYS 50 SUSTAIN 50 PEARS 50 COMMUNITY ASSOCIATION 50 CAPACITY 50 ERATO 50 TO HEAL 50 DESIRED 50 Central Venous Catheter 50 THE VOICE OF 50 NEEDS YOUR 50 EVALUATION 50 DIVIDEND PAYMENT 50 ROD 'S 50 LibiGel ® 50 pain palliation 50 REUTER 50 COLLABORATION 50 KAPPA 50 Lucentis ranibizumab Genentech 50 GROUP LIMITED ABN 50 orally dosed 50 FOCALIN XR 50 PARADIGM 50 BLUEPRINT FOR 50 Telmisartan 50 ASTRAL 50 intravenous AAT 50 Heparin Bioactive Surface 50 QUALITY OF 50 FEEL THE 50 NTx 50 AMISH 50 SUSTAINABLE ENERGY 50 TEOH 50 donepezil Aricept 50 sirolimus eluting 50 ZACTIMA 50 DYNA 50 STICK TO 50 CANDIDATE 'S 50 INSIGNIA 50 METRIC 50 LEVEE 50 COALITION FOR 50 Aptivus ® 50 Hydroxyurea 50 TRANS 50 KEEPING HIS 50 ACCREDITATION 50 ULORIC 50 CONCERTO 50 KRN# 50 MEDIA INC. 50 HIS OLD 50 OPAXIO TM 50 SIR Spheres 50 Orqis Medical 50 MOTIVATE 50 SHOP FOR 50 ARIXTRA 50 serotonin norepinephrine reuptake inhibitor 50 FIDUCIARY 50 REVERSE 50 GOLD LTD 50 MINERAL EXPLORATION 50 SCHOOL BOARDS 50 CONTRIBUTION 50 TO LISTEN 50 EVEREST II 50 RESILIENT 50 PREPARATORY 50 Implantable Defibrillator 50 KEY PERSONNEL 50 bivalirudin monotherapy 50 SECURITY SYSTEMS 50 QUALITY CARE 50 PROGRAM COORDINATOR 50 mesilate 50 QUAKER 50 reteplase 50 sargramostim 50 NORDIC 50 hydroxamic acid 50 Endarterectomy 50 BREAST CANCER 50 MOST ACTIVE 50 MIRACLE 50 unstable angina UA 50 BEST PRACTICE 50 platelet inhibitor 50 MAKING THEM 50 SPECIALISTS 50 SOME MORE 50 multicenter randomized clinical 50 GET INTO THE 50 DAPT Study 50 ARBITER 6 50 PLACEMENT OF 50 ESSENTIALS 50 FORMATION 50 ORGANIZATIONAL 50 IN STORE 50 Aggressive Drug Evaluation 50 BAL# [002] 50 multicenter Phase 50 azilsartan medoxomil 50 Estrogen Receptor 50 LESSONS IN 50 TAXUS TM 50 GET HER 50 COUNTING ON 50 CLINGING TO 50 GELA 50 NORTHSTAR 50 oral treprostinil 50 multicenter randomized double 50 GIVE YOURSELF 50 Kahalalide F 50 DISASTER RELIEF 50 APPROACH 50 octreotide 50 PAYING FOR 50 Factor VIIa 50 unresectable HCC 50 WOMEN 'S BUSINESS 50 PPAR gamma agonist 50 M4N 50 REAPING 50 preclinical efficacy 50 Granulocyte Colony Stimulating Factor 50 CRITICALLY 50 Medidur TM FA 50 DU #b 50 CYPHER 50 DEEP AF 50 GREEN HOUSE 50 METHOD 50 generation rotary VAD 50 tacrolimus ointment 50 MONITORING AND 50 GetGoal Phase III 50 FOR HUMAN RIGHTS 50 GRAVITY 50 Epirubicin 50 CLOSING THE